Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Open accessThe DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Recent studies indicate an increased frequency of mutations in the gene encoding glucocerebrosidase (GBA), a deficiency of which causes Gaucher's disease, among patients with Parkinson's disease. We aimed to ascertain the frequency of GBA mutations in an ethnically diverse group of patients with Parkinson's disease. METHODS: Sixteen centers participated in our international, collaborative study: five from the Americas, six from Europe, two from Israel, and three from Asia. Each center genotyped a standard DNA panel to permit comparison of the genotyping results across centers. Genotypes and phenotypic data from a total of 5691 patients with Parkinson's disease (780 Ashkenazi Jews) and 4898 controls (387 Ashkenazi Jews) were analyzed, with multivariate logistic-regression models and the Mantel-Haenszel procedure used to estimate odds ratios across centers. RESULTS: All 16 centers could detect two GBA mutations, L444P and N370S. Among Ashkenazi Jewish subjects, either mutation was found in 15% of patients and 3% of controls, and among non-Ashkenazi Jewish subjects, either mutation was found in 3% of patients and less than 1% of controls. GBA was fully sequenced for 1883 non-Ashkenazi Jewish patients, and mutations were identified in 7%, showing that limited mutation screening can miss half the mutant alleles. The odds ratio for any GBA mutation in patients versus controls was 5.43 across centers. As compared with patients who did not carry a GBA mutation, those with a GBA mutation presented earlier with the disease, were more likely to have affected relatives, and were more likely to have atypical clinical manifestations. CONCLUSIONS: Data collected from 16 centers demonstrate that there is a strong association between GBA mutations and Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A compartment located at the trans Golgi where autolysosomes and MTOR accumulate during RAS-induced senescence”
From Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). (2016) · cites this paper as [1769]
Experimental — accuracy not yet measuredIn the citing paper
“there is an increased frequency of mutations in the gene encoding GBA among patients with Parkinson’s disease (e.g. Aharon-Peretz et al. 2004; Clark et al. 2007; Gan-Or et al. 2008; Lwin et al. 2004), and vice versa (Sidransky et al. 2009).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
ON ESTIMATING THE RELATION BETWEEN BLOOD GROUP AND DISEASE
WOOLF, B. (1955) · Annals of Human Genetics · doi:10.1111/j.1469-1809.1955.tb01348.x · Cited by 2,723
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease
Neumann, J., Bras, J., Deas, E., O'Sullivan, S. S., Parkkinen, L., Lachmann, R. H., Li, A., Holton, J., Guerreiro, R., Paudel, R., et al. (2009) · Brain · doi:10.1093/brain/awp044 · Cited by 696 · cited 1×
“R496H (7 recombinant alleles) (10) c.84dupG ( 17 )”
Self-citationGaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)
Hruska, K. S., LaMarca, M. E., Scott, C. R., & Sidransky, E. (2008) · Human Mutation · doi:10.1002/humu.20676 · Cited by 678
Self-citationMutations in the Glucocerebrosidase Gene and Parkinson's Disease in Ashkenazi Jews
Aharon-Peretz, J., Rosenbaum, H., & Gershoni-Baruch, R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033277 · Cited by 597
Self-citationOccurrence of Parkinson's syndrome in type 1 Gaucher disease
Neudorfer, O., Giladi, N., Elstein, D., Abrahamov, A., Turezkite, T., Aghai, E., Reches, A., Bembi, B., & Zimran, A. (1996) · QJM · doi:10.1093/qjmed/89.9.691 · Cited by 401
Self-citationGaucher disease: complexity in a “simple” disorder
Sidransky, E. (2004) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2004.08.015 · Cited by 399 · cited 7×
“Patients 311 (0) 186:123 (2) NP 7 (2) Controls 473 (0) 267:206 64.1 8 ( 2 )”
InfluentialSelf-citationGlucocerebrosidase mutations in subjects with parkinsonism
Lwin, A. (2004) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2003.11.004 · Cited by 371
Parkinsonism among Gaucher disease carriers
Goker-Alpan, O., Schiffmann, R., LaMarca, M. E., Nussbaum, R. L., McInerney-Leo, A., & Sidransky, E. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2004.024455 · Cited by 366
Self-citation
Research works printed but not linked: 1
- 10.1002/(sici)1096-8652(199907)61:3<216::aid-ajh12>3.0.co;2-b · doi:10.1002/(sici)1096-8652(199907)61:3<216::aid-ajh12>3.0.co;2-b
Cited by
Items 401–500 of 1,008
Wang, C., Yang, T., Liang, M., Xie, J., & Song, N. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00265-y · Cited by 91
Limelight on Alpha-Synuclein: Pathological and Mechanistic Implications in Neurodegeneration
Wales, P., Pinho, R., Lázaro, D. F., & Outeiro, T. F. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130216 · Cited by 86
A cell culture model for monitoring α-synuclein cell-to-cell transfer
Reyes, J. F., Olsson, T. T., Lamberts, J. T., Devine, M. J., Kunath, T., & Brundin, P. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.07.003 · Cited by 83
“Moreover, single nucleotide polymorphisms around the α-syn locus have also been shown to be risk factors for sporadic PD in genome-wide association studies (Ramanan and Saykin, 2013; Sidransky et al., 2009).”
BackgroundThe GBAP1 pseudogene acts as a ceRNA for the glucocerebrosidase gene GBA by sponging miR-22-3p
Straniero, L., Rimoldi, V., Samarani, M., Goldwurm, S., Di Fonzo, A., Krüger, R., Deleidi, M., Aureli, M., Soldà, G., Duga, S., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-12973-5 · Cited by 87
Lysosome motility and distribution: Relevance in health and disease
Oyarzún, J. E., Lagos, J., Vázquez, M. C., Valls, C., De la Fuente, C., Yuseff, M. I., Alvarez, A. R., & Zanlungo, S. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.03.009 · Cited by 82
LRRK2 and α-Synuclein: Distinct or Synergistic Players in Parkinson’s Disease?
O’Hara, D. M., Pawar, G., Kalia, S. K., & Kalia, L. V. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00577 · Cited by 85
Penetrance of Glucocerebrosidase ( GBA ) Mutations in Parkinson's Disease: A Kin Cohort Study
Balestrino, R., Tùnesi, S., Tesei, S., Lopiano, L., Zecchinelli, A., & Goldwurm, S. (2020) · Movement Disorders · doi:10.1002/mds.28200 · Cited by 88
“Biallelic mutations on this gene cause Gaucher disease (GD), whereas monoallelic heterozygous mutations are the most important genetic risk factor for Parkinson’s disease (PD) currently known; between 5% and 25% of PD patients carry GBA mutations.(1,2) The penetrance of heterozygous GBA mutations by age 80 years (the…”
BackgroundLysosomes and α-synuclein form a dangerous duet leading to neuronal cell death
Bourdenx, M., Bezard, E., & Dehay, B. (2014) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2014.00083 · Cited by 81
Therapeutic applications of iminosugars: Current perspectives and future opportunities
Horne, G., & Wilson, F. X. (2011) · Progress in medicinal chemistry · doi:10.1016/b978-0-12-381290-2.00004-5 · Cited by 87
Minakaki, G., Krainc, D., & Burbulla, L. F. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.580634 · Cited by 93
Concise Review: Induced Pluripotent Stem Cell Research in the Era of Precision Medicine
Hamazaki, T., Rouby, N. M. E., Fredette, N. C., Santostefano, K. E., & Terada, N. (2017) · Stem Cells · doi:10.1002/stem.2570 · Cited by 95
Kumaran, R., & Cookson, M. R. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv236 · Cited by 86
Antioxidant Alternatives in the Treatment of Amyotrophic Lateral Sclerosis: A Comprehensive Review
Carrera‐Juliá, S., Moreno, M. L., Barrios, C., Ortí, J. E. D. L. R., & Drehmer, E. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00063 · Cited by 93
“In the case of PD, the repletion of NAD+ through the use of NR prevents aging related to the loss of dopaminergic neurons and the reduction of motor function in Drosophila fly model of PD (Sidransky et al., 2009).”
BackgroundGöker-Alpan, Ö., Masdeu, J. C., Kohn, P. D., Ianni, A. M., Lopez, G. J., Groden, C. A., Chapman, M. C., Cropp, B., Eisenberg, D. P., Maniwang, E., et al. (2012) · Brain · doi:10.1093/brain/aws174 · Cited by 93
Self-citationKilpatrick, B. S., Magalhaes, J., Beavan, M. S., McNeill, A., Gegg, M. E., Cleeter, M. W. J., Bloor-Young, D., Churchill, G. C., Duchen, M. R., Schapira, A. H., et al. (2016) · Cell Calcium · doi:10.1016/j.ceca.2015.11.002 · Cited by 84
Review: The spectrum of clinical features seen with alpha synuclein pathology
Barker, R., & Williams‐Gray, C. H. (2016) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12303 · Cited by 96
“glucocerebrosidase gene are the commonest genetic risk factor for PD,(74, 75) and opened up a new”
BackgroundEpigenetics in Parkinson’s Disease
Pavlou, M. A. S., & Outeiro, T. F. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-53889-1_19 · Cited by 95
Genetics of Parkinson's Disease
Koros, C., Simitsi, A., & Stefanis, L. (2017) · International review of neurobiology · doi:10.1016/bs.irn.2017.01.009 · Cited by 97
Hallett, P. J., Huebecker, M., Brekk, O. R., Moloney, E. B., Rocha, E. M., Priestman, D. A., Platt, F. M., & Isacson, O. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.02.028 · Cited by 87
Association of Dual LRRK2 G2019S and GBA Variations With Parkinson Disease Progression
Ortega, R. A., Wang, C., Raymond, D., Bryant, N., Scherzer, C. R., Thaler, A., Alcalay, R. N., West, A. B., Mirelman, A., Kuras, Y. I., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.5845 · Cited by 89
Self-citationUpdate on CSF Biomarkers in Parkinson’s Disease
Kwon, E. H., Tennagels, S., Gold, R., Gerwert, K. B., Beyer, L., & Tönges, L. (2022) · Biomolecules · doi:10.3390/biom12020329 · Cited by 95
“This hypothesis is strengthened by the identification of mutations in the GBA gene, encoding the lysosomal enzyme glucocerebrosidase (GCase), as the most common genetic risk factor for PD [60,61].”
BackgroundTowards a complete resolution of the genetic architecture of disease
Singleton, A. B., Hardy, J., Traynor, B. J., & Houlden, H. (2010) · Trends in Genetics · doi:10.1016/j.tig.2010.07.004 · Cited by 86
Self-citationMolecular pathogenesis of Parkinson's disease: update
Saiki, S., Sato, S., & Hattori, N. (2011) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-301205 · Cited by 105
Van der Lienden, M. J. C., Gaspar, P., Boot, R., Aerts, J. M. F. G., & Van Eijk, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010066 · Cited by 84
Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote α-synuclein aggregation
Galvagnion, C., Marlet, F. R., Cerri, S., Schapira, A. H. V., Blandini, F., & Monte, D. A. D. (2021) · Brain · doi:10.1093/brain/awab371 · Cited by 91
Parkinson’s disease mouse models in translational research
Antony, P. M. A., Diederich, N. J., & Balling, R. (2011) · Mammalian Genome · doi:10.1007/s00335-011-9330-x · Cited by 91
Systemic gene delivery to the central nervous system using Adeno-associated virus
Bourdenx, M., Dutheil, N., Bezard, E., & Dehay, B. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00050 · Cited by 79
“In this particular disorder, brain pathology can be detected in utero and death occurs within the two first years of age (Sidransky et al., 2009).”
BackgroundZhang, Y., Li, S., Sun, Q., Zhou, X. C., Pan, H., Guo, J., & Tang, B. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00043 · Cited by 89
“Due the prominent ethnic heterogeneity, especially in AJ and non-AJ populations (Sidransky et al., 2009; Sun et al., 2010), of GBA mutations in PD in different regions, all ethnicities information including AJ, non-AJ (Africans, European/West Asians, Hispanics, East Asians, Mixed:composed of at least two different gro…”
BackgroundInfluentialClinicogenetic study of GBA mutations in patients with familial Parkinson's disease
Li, Y., Sekine, T., Funayama, M., Li, L., Yoshino, H., Nishioka, K., Tomiyama, H., & Hattori, N. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.09.019 · Cited by 91
Functionalization of the TMEM175 p.M393T variant as a risk factor for Parkinson disease
Jinn, S., Blauwendraat, C., Toolan, D., Gretzula, C. A., Drolet, R. E., Smith, S., Nalls, M. A., Marcus, J., Singleton, A. B., & Stone, D. J. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz136 · Cited by 80
“Furthermore, the fourth most significant signal is believed to be driven by GBA (glucocerebrocidase), an established risk factor for PD and Gaucher disease (10).”
BackgroundInfluentialSelf-citationHeterogeneity-aware and communication-efficient distributed statistical inference
Duan, R., Ning, Y., & Chen, Y. (2021) · Biometrika · doi:10.1093/biomet/asab007 · Cited by 115
Gene Therapy for Parkinson’s Disease Associated with GBA1 Mutations
Abeliovich, A., Hefti, F. F., & Sevigny, J. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-212739 · Cited by 102
A generalizable hypothesis for the genetic architecture of disease: pleomorphic risk loci
Singleton, A., & Hardy, J. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr358 · Cited by 83
Self-citationUemura, N., Koike, M., Ansai, S., Kinoshita, M., Ishikawa‐Fujiwara, T., Matsui, H., Naruse, K., Sakamoto, N., Uchiyama, Y., Todo, T., et al. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005065 · Cited by 88
Oligomeric α-synuclein and glucocerebrosidase activity levels in GBA-associated Parkinson’s disease
Пчелина, С. Н., Emelyanov, A., Baydakova, G., Andoskin, P. A., Senkevich, K. A., Nikolaev, M. A., Miliukhina, I. V., Yakimovskii, А. F., Timofeeva, A., Fedotova, E. Y., et al. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.10.039 · Cited by 87
Beilina, A., Bonet-Ponce, L., Kumaran, R., Kordich, J. J., Ishida, M., Mamais, A., Kaganovich, A., Saez-Atienzar, S., Gershlick, D. C., Roosen, D. A., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107614 · Cited by 82
“Although categorization of the function of all PD risk genes is incomplete, variation in genes encoding endo-lysosomal proteins appears to play a strong role in PD risk (Bras et al., 2008; Sidransky et al., 2009).”
Genetic variability at the PARK16 locus
Tucci, A., Nalls, M. A., Houlden, H., Revesz, T., Singleton, A. B., Wood, N. W., Hardy, J., & Paisán-Ruiz, C. (2010) · European Journal of Human Genetics · doi:10.1038/ejhg.2010.125 · Cited by 81
Self-citationLees, A. J., Fahn, S., Eggert, K. M., Jankovic, J. J., Lang, A. E., Micheli, F. E., Mouradian, M. M., Oertel, W. H., Olanow, C. W., Poewe, W. H., et al. (2011) · Movement Disorders · doi:10.1002/mds.23983 · Cited by 83
Self-citationThe genetics of Parkinson's disease
Mullin, S., & Schapira, A. (2015) · British Medical Bulletin · doi:10.1093/bmb/ldv022 · Cited by 78
Assessment of a Targeted Gene Panel for Identification of Genes Associated With Movement Disorders
Montaut, S., Tranchant, C., Drouot, N., Rudolf, G., Guissart, C., Tarabeux, J., Stemmelen, T., Velt, A., Fourrage, C., Nitschké, P., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.1478 · Cited by 88
Progranulin deficiency leads to reduced glucocerebrosidase activity
Zhou, X., Paushter, D. H., Pagan, M. D., Kim, D., Nunez Santos, M., Lieberman, R. L., Overkleeft, H. S., Sun, Y., Smolka, M. B., & Hu, F. (2019) · PLOS ONE · doi:10.1371/journal.pone.0212382 · Cited by 82
Hu, L., Dong, M.-X., Huang, Y.-L., Lu, C.-Q., Qian, Q., Zhang, C.-C., Xu, X.-M., Liu, Y., Chen, G.-H., & Wei, Y.-D. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00080 · Cited by 82
Impaired autophagy: The collateral damage of lysosomal storage disorders
Myerowitz, R., Puertollano, R., & Raben, N. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.103166 · Cited by 85
“While the most common Type 1 displays no neuropathic involvement at onset during early childhood years, Gaucher patients as well as heterozygote carriers appear to harbor an increased risk for the development of Parkinson’s disease later in life [36,37].”
BackgroundRecent advances in Parkinson’s disease genetics
Lubbe, S. J., & Morris, H. R. (2013) · Journal of Neurology · doi:10.1007/s00415-013-7003-2 · Cited by 86
Analysis of GWAS-linked loci in Parkinson disease reaffirms PARK16 as a susceptibility locus
Tan, E.-K., Kwok, H.-K., Tan, L. C., Zhao, W.-T., Prakash, K. M., Au, W.-L., Pavanni, R., Ng, Y.-Y., Satake, W., Zhao, Y., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181eccfcd · Cited by 78
Self-citationDLB and PDD: a role for mutations in dementia and Parkinson disease genes?
Meeus, B., Verstraeten, A., Crosiers, D., Engelborghs, S., den Broeck, M. V., Mattheijssens, M., Peeters, K., Corsmit, E., Elinck, E., Pickut, B. A., et al. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.10.014 · Cited by 86
Genetics of neurodegenerative diseases: insights from high-throughput resequencing
Tsuji, S. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq162 · Cited by 80
Self-citationAlessi, D. R., & Pfeffer, S. R. (2024) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-030122-051144 · Cited by 79
Delineating pathological pathways in a chemically induced mouse model of Gaucher disease
Vardi, A., Zigdon, H., Meshcheriakova, A., Klein, A. D., Yaacobi, C., Eilam, R., Kenwood, B. M., Rahim, A. A., Massaro, G., Merrill, A. H., et al. (2016) · The Journal of Pathology · doi:10.1002/path.4751 · Cited by 84
β-adrenoreceptors and the risk of Parkinson's disease
Hopfner, F., Höglinger, G. U., Kuhlenbäumer, G., Pottegård, A., Wod, M., Christensen, K., Tanner, C. M., & Deuschl, G. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30400-4 · Cited by 89
GBA Variants in Parkinson's Disease: Clinical, Metabolomic, and Multimodal Neuroimaging Phenotypes
Greuel, A., Trezzi, J., Glaab, E., Ruppert, M. C., Maier, F., Jäger, C., Hodak, Z., Lohmann, K., Ma, Y., Eidelberg, D., et al. (2020) · Movement Disorders · doi:10.1002/mds.28225 · Cited by 85
“1%); similar rates of a positive family history are regularly reported in GBA mutations.(1,7) A metaanalysis has not found higher UPDRS-III scores in variant carriers,(16) whereas LEDD may be increased(11) and should be investigated longitudinally in larger cohorts.”
BackgroundSex Differences in Parkinson’s Disease: From Bench to Bedside
Russillo, M. C., Andreozzi, V., Erro, R., Picillo, M., Amboni, M., Cuoco, S., Barone, P., & Pellecchia, M. T. (2022) · Brain Sciences · doi:10.3390/brainsci12070917 · Cited by 80
Parkinson’s Disease and Cognitive Impairment
Yang, Y., Tang, B., & Guo, J. (2016) · Parkinson s Disease · doi:10.1155/2016/6734678 · Cited by 90
Insights into the structural biology of Gaucher disease
Smith, L., Mullin, S., & Schapira, A. H. V. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.09.010 · Cited by 87
Exploring genetic modifiers of Gaucher disease: The next horizon
Davidson, B. A., Hassan, S., Garcia, E. J., Tayebi, N., & Sidransky, E. (2018) · Human Mutation · doi:10.1002/humu.23611 · Cited by 84
Self-citationA perilous path: the inborn errors of sphingolipid metabolism
Dunn, T. M., Tifft, C. J., & Proia, R. L. (2019) · Journal of Lipid Research · doi:10.1194/jlr.s091827 · Cited by 84
C-terminal α-synuclein truncations are linked to cysteine cathepsin activity in Parkinson’s disease
McGlinchey, R. P., Lacy, S. M., Huffer, K., Tayebi, N., Sidransky, E., & Lee, J. C. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.008930 · Cited by 83
“One intriguing implication is how they could play a role in the reciprocal relationship between levels of -syn and the lysosomal hydrolase glucocerebrosidase (GCase) (51), which is currently recognized as the most prevalent genetic risk factor for the development of PD and DLB (52, 53).”
BackgroundInfluentialSelf-citationValdez, C., Ysselstein, D., Young, T. J., Zheng, J., & Krainc, D. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddz229 · Cited by 80
“Heterozygous mutations in GBA1, which lead to reduced GCase activity, are a well-established genetic risk factor for Parkinson disease and Lewy body dementia (58, 63).”
BackgroundMechanisms of alpha-synuclein toxicity: An update and outlook
(2020) · Progress in Brain Research · doi:10.1016/bs.pbr.2019.10.005 · Cited by 75
Baseline genetic associations in the Parkinson's Progression Markers Initiative (PPMI)
Nalls, M. A., Keller, M. F., Hernandez, D. G., Chen, L., Stone, D. J., Singleton, A., & on behalf of the Parkinson's Progression Marker Initiative (PPMI) investigators (2015) · Movement Disorders · doi:10.1002/mds.26374 · Cited by 80
Self-citationAugmented frontal cortex diacylglycerol levels in Parkinson’s disease and Lewy Body Disease
Wood, P. L., Tippireddy, S., Feriante, J., & Woltjer, R. L. (2018) · PLOS ONE · doi:10.1371/journal.pone.0191815 · Cited by 74
GBA variants in REM sleep behavior disorder: A multicenter study
Krohn, L., Ruskey, J. A., Rudakou, U., Léveillé, E., Asayesh, F., Hu, M. T. M., Arnulf, I., Dauvilliers, Y. A., Högl, B., Stefani, A., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000010042 · Cited by 82
Self-citationAlafuzoff, I. I., & Hartikainen, P. H. (2017) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802395-2.00024-9 · Cited by 85
Daykin, E. C., Ryan, E., & Sidransky, E. (2021) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2021.01.002 · Cited by 77
“The connection between GBA1 variants and PD has been well established [150], with the lifetime risk currently of developing PD thought to be around 5–20% in patients with GD.”
BackgroundSelf-citationQuality control gone wrong: mitochondria, lysosomal storage disorders and neurodegeneration
Osellame, L. D., & Duchen, M. R. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12453 · Cited by 84
A characterization of Gaucher iPS-derived astrocytes: Potential implications for Parkinson's disease
Aflaki, E., Stubblefield, B. K., McGlinchey, R. P., McMahon, B., Ory, D. S., & Sidransky, E. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104647 · Cited by 77
Self-citationGlucocerebrosidase-associated Parkinson disease: Pathogenic mechanisms and potential drug treatments
Gegg, M. E., Menozzi, E., & Schapira, A. H. V. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105663 · Cited by 83
The relationship of alpha-synuclein to mitochondrial dynamics and quality control
Thorne, N. J., & Tumbarello, D. A. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.947191 · Cited by 82
Wu, G., Wang, X., Feng, X., Zhang, A., Li, J., Gu, K., Huang, J. A., Pang, S., Dong, H., Gao, H., et al. (2011) · Brain Research · doi:10.1016/j.brainres.2011.04.013 · Cited by 83
“Mutations in lysosomal glucocerebrosidase gene, which cause lysosomal storage disease-Gaucher's disease, have recently been implicated in PD (Aharon-Peretz et al., 2004; Sidransky et al., 2009).”
Overcoming obstacles in Parkinson's disease
Sherer, T., Chowdhury, S., Peabody, K., & Brooks, D. W. (2012) · Movement Disorders · doi:10.1002/mds.25260 · Cited by 93
Acid ceramidase inhibition ameliorates α-synuclein accumulation upon loss of GBA1 function
Kim, M. J., Jeon, S., Burbulla, L. F., & Krainc, D. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy105 · Cited by 81
The Identification of Alpha-Synuclein as the First Parkinson Disease Gene
Nussbaum, R. L. (2017) · Journal of Parkinson s Disease · doi:10.3233/jpd-179003 · Cited by 77
The L444P Gba1 mutation enhances alpha-synuclein induced loss of nigral dopaminergic neurons in mice
Migdalska‐Richards, A., Węgrzynowicz, M., Rusconi, R., Deangeli, G., Monte, D. A. D., Spillantini, M. G., & Schapira, A. H. V. (2017) · Brain · doi:10.1093/brain/awx221 · Cited by 79
“…features (including depression, anxiety, sleep disturbance and hallucinations) and a tendency to earlier and more prevalent cognitive impairment (Tan et al., 2007; Neumann et al., 2009; Sidransky et al., 2009; Brockmann et al., 2011; McNeill et al., 2012b; Winder-Rhodes et al., 2013).”
BackgroundSchneider, J. S. (2018) · PLoS ONE · doi:10.1371/journal.pone.0199189 · Cited by 77
Dysregulation of the autophagic-lysosomal pathway in Gaucher and Parkinson's disease
Pitcairn, C., Wani, W. Y., & Mazzulli, J. R. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.03.008 · Cited by 75
Sardi, S. P., Cheng, S. H., & Shihabuddin, L. S. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.12.001 · Cited by 80
Parkinson's disease: acid‐glucocerebrosidase activity and alpha‐synuclein clearance
Blanz, J., & Saftig, P. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13517 · Cited by 71
Movement Disorders in Treatable Inborn Errors of Metabolism
Ebrahimi‐Fakhari, D., van Karnebeek, C., & Münchau, A. M. (2018) · Movement Disorders · doi:10.1002/mds.27568 · Cited by 78
“Parkinsonism in late adolescence or adulthood is a feature in several IEMs, including storage diseases such lysosomal storage disorders (i.e., NPC, different forms of neuronal ceroid lipofuscinoses, or GM2-gangliosidosis40), primary familial brain calcification51 or cerebrotendinous xanthomatosis.48,52 Of note, there…”
BackgroundVandendriessche, C., Bruggeman, A., Van Cauwenberghe, C., & Vandenbroucke, R. E. (2020) · Cells · doi:10.3390/cells9112485 · Cited by 73
“Up to 7% of PD patients carry a mutation in the GBA1 gene [113], whereas PD patients that do not carry a GBA1 mutation also show a significant reduction in lysosomal GCase activity [114,115].”
BackgroundIntestinal Inflammation and Parkinson’s Disease
Li, Y., Chen, Y., Jiang, L., Zhang, J., Tong, X., Chen, D., & Le, W. (2021) · Aging and Disease · doi:10.14336/ad.2021.0418 · Cited by 82
Parkinson’s Disease is Predominantly a Genetic Disease
Lim, S., & Klein, C. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-230376 · Cited by 90
Neuropathology and Neurochemistry of Nonmotor Symptoms in Parkinson's Disease
Ferrer, I. (2011) · Parkinson's Disease · doi:10.4061/2011/708404 · Cited by 71
Winder‐Rhodes, S. E., Garcia‐Reitböck, P., Ban, M., Evans, J. R., Jacques, T. S., Kemppinen, A., Foltynie, T., Williams‐Gray, C. H., Chinnery, P. F., Hudson, G., et al. (2012) · Movement Disorders · doi:10.1002/mds.24029 · Cited by 75
Premotor biomarkers for Parkinson's disease - a promising direction of research
Haas, B. R., Stewart, T. H., & Zhang, J. (2012) · Translational Neurodegeneration · doi:10.1186/2047-9158-1-11 · Cited by 81
The Mutation Matters: CSF Profiles of GCase , Sphingolipids, α‐Synuclein in PD GBA
Lerche, S., Schulte, C., Wurster, I., Machetanz, G., Röeben, B., Zimmermann, M., Deuschle, C., Hauser, A., Böhringer, J., Krägeloh‐Mann, I., et al. (2021) · Movement Disorders · doi:10.1002/mds.28472 · Cited by 78
Self-citationYadavalli, N., & Ferguson, S. M. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2303789120 · Cited by 81
Benitez, B. A., Davis, A. A., Jin, S. C., Ibanez, L., Ortega-Cubero, S., Pastor, P., Choi, J., Cooper, B., Perlmutter, J. S., & Cruchaga, C. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0097-0 · Cited by 75
“L483P) have consistently been reported to be associated with increased PD risk in both, Ashkenazi Jewish and nonAshkenazi populations [29].”
BackgroundResultInfluentialGündner, A. L., Durán-Pacheco, G., Zimmermann, S., Ruf, I., Moors, T. E., Baumann, K., Jagasia, R., van de Berg, W. D. J., & Kremer, T. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.09.015 · Cited by 80
Impact of Parkinson's disease risk loci on age at onset
Lill, C. M., Hansen, J., Olsen, J. H., Binder, H., Ritz, B., & Bertram, L. (2015) · Movement Disorders · doi:10.1002/mds.26237 · Cited by 72
Parkinson's disease in a dish – Using stem cells as a molecular tool
Badger, J. L., Llana, O. C., Hartfield, E. M., & Wade‐Martins, R. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.08.035 · Cited by 87
Pro-cathepsin D, Prosaposin, and Progranulin: Lysosomal Networks in Parkinsonism
Tayebi, N., Lopez, G. J., Do, J., & Sidransky, E. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.07.004 · Cited by 77
Self-citationLipidomics of Bioactive Lipids in Alzheimer’s and Parkinson’s Diseases: Where Are We?
Chiurchiù, V., Tiberi, M., Matteocci, A., Fazio, F., Siffeti, H., Saracini, S., Mercuri, N. B., & Sancesario, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116235 · Cited by 64
The contribution of mutantGBAto the development of Parkinson disease inDrosophila
Maor, G., Cabasso, O., Krivoruk, O., Rodriguez, J., Steller, H., Segal, D., & Horowitz, M. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw129 · Cited by 88
Yang, S., Beavan, M. S., Chau, K., Taanman, J., & Schapira, A. H. V. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.01.011 · Cited by 78
An early diagnosis is not the same as a timely diagnosis of Parkinson's disease
Rees, R. N., Acharya, A., Schrag, A. E., & Noyce, A. J. (2018) · F1000Research · doi:10.12688/f1000research.14528.1 · Cited by 80
Smolders, S., & Broeckhoven, C. V. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00935-4 · Cited by 75
“43) of developing PD in heterozygous and homozygous GBA mutation carriers [313].”
BackgroundMenozzi, E., & Schapira, A. H. V. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.694764 · Cited by 80
Alpha-Synuclein and Lipids: The Elephant in the Room?
Sarchione, A., Marchand, A., Taymans, J.-M., & Chartier-Harlin, M.-C. (2021) · Cells · doi:10.3390/cells10092452 · Cited by 66
Identification of a Biomarker in Cerebrospinal Fluid for Neuronopathic Forms of Gaucher Disease
Zigdon, H., Savidor, A., Levin, Y., Meshcheriakova, A., Schiffmann, R., & Futerman, A. H. (2015) · PLOS ONE · doi:10.1371/journal.pone.0120194 · Cited by 72
Matsui, H., Sato, F., Sato, S., Koike, M., Taruno, Y., Saiki, S., Funayama, M., Ito, H., Taniguchi, Y., Uemura, N., et al. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.02.046 · Cited by 71
Metadata
- Authors
- Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., Chen, C.-M., Clark, L. N., Condroyer, C., De Marco, E. V., Dürr, A., Eblan, M. J., Fahn, S., Farrer, M. J., Fung, H.-C., Gan-Or, Z., Gasser, T., Gershoni-Baruch, R., Giladi, N., Griffith, A., Gurevich, T., Januario, C., Kropp, P., Lang, A. E., Lee-Chen, G.-J., Lesage, S., Marder, K., Mata, I. F., Mirelman, A., Mitsui, J., Mizuta, I., Nicoletti, G., Oliveira, C., Ottman, R., Orr-Urtreger, A., Pereira, L. V., Quattrone, A., Rogaeva, E., Rolfs, A., Rosenbaum, H., Rozenberg, R., Samii, A., Samaddar, T., Schulte, C., Sharma, M., Singleton, A., Spitz, M., Tan, E.-K., Tayebi, N., Toda, T., Troiano, A. R., Tsuji, S., Wittstock, M., Wolfsberg, T. G., Wu, Y.-R., Zabetian, C. P., Zhao, Y., & Ziegler, S. G.
- Affiliations
- National Institutes of Health (US)
- National Human Genome Research Institute (US)
- Corresponding author
- Sidransky, E.
- ORCID
- Sidransky, E.
- Nalls, M.A.
- Aasly, J.O.
- Annesi, G.
- Barbosa, E.R.
- Berg, D.
- Brice, A.
- Chen, C.-M.
- Clark, L.N.
- Condroyer, C.
- Dürr, A.
- Farrer, M.J.
- Fung, H.-C.
- Gasser, T.
- Giladi, N.
- Gurevich, T.
- Kropp, P.
- Lang, A.E.
- Lesage, S.
- Marder, K.
- Mata, I.F.
- Mirelman, A.
- Mitsui, J.
- Mizuta, I.
- Nicoletti, G.
- Oliveira, C.
- Ottman, R.
- Pereira, L.V.
- Quattrone, A.
- Rogaeva, E.
- Rosenbaum, H.
- Rozenberg, R.
- Schulte, C.
- Sharma, M.
- Singleton, A.
- Spitz, M.
- Tan, E.-K.
- Tayebi, N.
- Toda, T.
- Tsuji, S.
- Wittstock, M.
- Wolfsberg, T.G.
- Wu, Y.-R.
- Zabetian, C.P.
- Zhao, Y.
- Ziegler, S.G.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-10-22
- Volume
- 361
- Issue
- 17
- Pages
- 1651-1661
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC2856322
- OpenAlex
- W2170281382
- Cited by
- 2,135
- References
- 43
- Citations by year
- 2026: 128 · 2025: 147 · 2024: 156 · 2023: 156 · 2022: 149 · 2021: 155 · 2020: 174 · 2019: 136 · 2018: 135 · 2017: 115 · 2016: 118 · 2015: 118 · 2014: 95 · 2013: 103 · 2012: 84
- FWCI
- 54.96
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Scientific Electronic Library Online (São Paulo Research Foundation, Latin American and Caribbean Center on Health Sciences Information, Conselho Nacional de Desenvolvimento Científico e Tecnológico) (publishedVersion)
- PubMed Central (acceptedVersion)
- National University of Singapore (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- University of Washington
- National Institutes of Health (Z99 HG999999)
- National Institute on Aging (Z01AG000957)
- National Human Genome Research Institute (ZIAHG200336)
- National Institute of Neurological Disorders and Stroke (R56NS036630, R21NS050487, NS 40256, NS050487, R01NS036630, R01NS060113, NS060113)
- National Center for Research Resources (UL1RR024156)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Keywords
- Parkinson's disease, glucocerebrosidase, GBA mutations, Ashkenazi Jews, Gaucher disease, mutation frequency, genotype-phenotype correlation, atypical presentation, familial Parkinson's disease
- MeSH terms
- Aged, Genotype, Glucosylceramidase, Humans, Jews, Middle Aged, Mutation, Parkinson Disease, Multivariate Analysis, Logistic Models, Odds Ratio, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.